Martina Kaniakova

Martina Kaniakova

Auto-generated profile, based on publicly available information

Martina Kaniakova

Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i., Videnska 1083, 14220 Prague 4, Czech Republic

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
JKJan Korabecny
Jan Korabecny
RPRonald S. Petralia
Ronald S. Petralia
MKMartina Kaniakova
Martina Kaniakova
NSNathalie Sans
Nathalie Sans
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. There are three distinct subtypes of ionotropic glutamate receptors that have been identified including 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid receptors (AMPARs), N-methyl-D-aspartate receptors (NMDARs) and kainate receptors. The most common glutamate receptors in mature synapses are AMPARs that mediate the fast excitatory neurotransmission and NMDARs that mediate the slow excitatory neurotransmission. There have been large numbers of recent reports studying how a single neuron regulates synaptic numbers and types of AMPARs and NMDARs. Our current research is centered primarily on NMDARs and, therefore, we will focus in this review on recent knowledge of molecular mechanisms occurring 1) early in the biosynthetic pathway of NMDARs, 2) in the transport of NMDARs after their release from the endoplasmic reticulum, and 3) at the plasma membrane including excitatory synapses. Because a growing body of evidence also indicates that abnormalities in NMDAR functioning are associated with a number of human psychiatric and neurological diseases, this review together with other chapters in this issue may help to enhance research and to gain further knowledge of normal synaptic physiology as well as of the etiology of many human brain diseases.

24 March 2015 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
MKMiloslav Korinek
Miloslav Korinek
VVVojtech Vyklicky
Vojtech Vyklicky
JBJirina Borovska
Jirina Borovska
KLKatarina Lichnerova
Katarina Lichnerova
MKMartina Kaniakova
Martina Kaniakova
LVLadislav Vyklický
Ladislav Vyklický

18 June 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VVVojtech Vyklicky
Vojtech Vyklicky
BKBarbora Krausova
Barbora Krausova
JCJiri Cerny
Jiri Cerny
ABAles Balik
Ales Balik
MZMartin Zapotocky
Martin Zapotocky
LVLadislav Vyklický
Ladislav Vyklický
N-methyl-D-aspartate receptors (NMDARs) mediate synaptic plasticity and their dysfunction is implicated in multiple brain disorders. NMDARs can be allosterically modulated by numerous compounds, including endogenous neurosteroid pregnanolone sulfate. Here, we identify the molecular basis of the use-dependent and voltage-independent inhibitory effect of neurosteroids on NMDAR responses. The site of action is located at the extracellular vestibule of the receptor’s ion channel pore and is accessible after receptor activation. Mutations in the extracellular vestibule in the SYTANLAAF motif disrupt the inhibitory effect of negatively charged steroids. In contrast, positively charged steroids inhibit mutated NMDAR responses in a voltage-dependent manner. These results, in combination with molecular modeling, characterize structure details of the open configuration of the NMDAR channel. Our results provide a unique opportunity for the development of new therapeutic neurosteroid-based ligands to treat diseases associated with dysfunction of the glutamate system.

1 September 2013 in Current Alzheimer Research
Verified
Journal Article
Closed access
Ondrej SoukupOndrej Soukup
Ondrej Soukup
DJDaniel Jun
Daniel Jun
JKJana Zdarova Karasova
Jana Zdarova Karasova
JPJiri Patocka
Jiri Patocka
KMKamil Musilek
Kamil Musilek
KKKamil Kuca
Kamil Kuca
Alzheimer´s disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from the market particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7- MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound – tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the tests related to a possible AD treatment. Only the pharmacokinetics and a higher acetylcholinesterase and butyrylcholinesterase inhibitory potency would slightly give advantages to tacrine over 7-MEOTA, but concerning its lower toxicity, better antioxidant properties, interaction with muscarinic and nicotinic receptors and “safer” metabolization provide strong evidence for reconsider 7-MEOTA and its derivatives as candidate molecules for the treatment of AD.

1 April 2017 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JKJan Korabecny
Jan Korabecny
KHKristina Holubova
Kristina Holubova
Eugenie  NepovimovaEugenie Nepovimova
Eugenie Nepovimova
JKJan Krusek
Jan Krusek
MKMartina Kaniakova
Martina Kaniakova
Ondrej SoukupOndrej Soukup
Ondrej Soukup

1 July 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KLKatarina Lichnerova
Katarina Lichnerova
MKMartina Kaniakova
Martina Kaniakova
SPSeung Pyo Park
Seung Pyo Park
KSKristyna Skrenkova
Kristyna Skrenkova
YWYa-Xian Wang
Ya-Xian Wang
JKJan Korabecny
Jan Korabecny
N-methyl-D-aspartate receptors (NMDARs) comprise a subclass of neurotransmitter receptors whose surface expression is regulated at multiple levels, including processing in the endoplasmic reticulum (ER), intracellular trafficking via the Golgi apparatus, internalization, recycling, and degradation. With respect to early processing, NMDARs are regulated by the availability of GluN subunits within the ER, the presence of ER retention and export signals, and post-translational modifications, including phosphorylation and palmitoylation. However, the role of N-glycosylation, one of the most common post-translational modifications, in regulating NMDAR processing has not been studied in detail. Using biochemistry, confocal and electron microscopy, and electrophysiology in conjunction with a lentivirus-based molecular replacement strategy, we found that NMDARs are released from the ER only when two asparagine residues in the GluN1 subunit (N203 and N368) are N-glycosylated. Although GluN2A and GluN2B subunits are also N-glycosylated, their N-glycosylation sites do not appear to be essential for surface delivery of NMDARs. Furthermore, we found that removing N-glycans from native NMDARs altered the receptor affinity for glutamate. Our results suggest a novel mechanism by which neurons ensure that postsynaptic membranes contain sufficient numbers of functional NMDARs.